FDA approved

FDA approval belongs to a specific product, not to an ingredient. A company (FDA calls it the applicant or sponsor) applies for approval of its drug product. When FDA approves the application, its approval letter allows that company to market that product in the US. FDA says approval means its drug center has reviewed data on the drug's effects and decided that the benefits outweigh the known and potential risks for the intended population.

The approval is tied to the product's label, which FDA calls the official description of the drug product. The label sets out the conditions the product is approved to treat, its dosage form (a tablet or an injection, for example) and how it's given. FDA calls use outside those terms, such as for another condition or given in a different way, "unapproved use" of an approved drug.

Two things follow from this:

  • Another product with the same active ingredient needs its own approval. Generic medicines, for example, are approved through applications of their own. Our guide to GLP-1 brands and their active ingredients shows this for semaglutide and tirzepatide.
  • A compounded or other unapproved product doesn't share a brand's approval, even if it contains the same active ingredient.

Approved, cleared and registered

These words aren't interchangeable. "Approved" is used for drugs, and for the highest-risk (Class III) medical devices, which generally need premarket approval. Many other devices are "cleared" through a 510(k): FDA agrees the device is substantially equivalent to one already legally on the market. In FDA's words, "mere registration of an establishment or listing of a drug or device does not denote approval." So a pharmacy or product being registered with FDA doesn't make it FDA-approved.

How to check if a medicine is FDA approved

  1. Find the names on the box or pharmacy label: the brand name, if it has one, and the active ingredient.
  2. Search Drugs@FDA for either name. An approved product is listed under its application, with its dosage form, route and marketing status.
  3. Check that it matches what you have: the same product, dosage form and route. An approval for an injection doesn't cover a tablet, and an approved brand doesn't cover a compounded version.
  4. For generics, FDA's Orange Book identifies drug products approved on the basis of safety and effectiveness, with FDA's therapeutic equivalence evaluations.

Drugs@FDA (fda.gov/drugsatfda) is FDA's database of approved drug products for human use. Each application lists its products with their dosage form, route and marketing status; "Discontinued" means an approved product that isn't currently marketed, or never was. DailyMed, from the National Library of Medicine at NIH, publishes the labeling companies submit to FDA, but a listing there isn't proof of approval: it also lists some products FDA doesn't approve, such as dietary supplements. Our guide to reading an FDA drug label walks through searching both.

Investigational

FDA calls drugs that are being tested but aren't yet approved "investigational" or "experimental" drugs. Federal law generally requires a drug to have an approved application before it's shipped across state lines. An Investigational New Drug application (IND) is how a study's sponsor gets FDA's exemption from that rule, so the drug can go to the researchers running its clinical trials.

Clinical trials run in phases. Our guide to what clinical trial phases mean explains Phase 1, 2 and 3.

Compounded

FDA describes compounding as a licensed pharmacist or physician (or, at an outsourcing facility, a person supervised by a licensed pharmacist) combining, mixing or altering a drug's ingredients to make a medication tailored to an individual patient's needs. Federal law sets out two routes:

  • 503A pharmacies: compounding by a licensed pharmacist or physician under section 503A of the Federal Food, Drug, and Cosmetic Act. These compounders aren't subject to FDA's current good manufacturing practice (CGMP) requirements.
  • 503B outsourcing facilities: facilities registered with FDA as outsourcing facilities under section 503B. FDA is their main overseer, inspects them on a risk-based schedule and requires them to meet CGMP requirements.

"Compounded drugs are not FDA-approved," FDA says. That means FDA doesn't verify their safety, effectiveness or quality before they're marketed. This holds even when a compounded drug contains the same active ingredient as an approved medicine.

Compounded semaglutide and tirzepatide

Semaglutide is the active ingredient in Ozempic, Wegovy and Rybelsus, and tirzepatide is the active ingredient in Mounjaro and Zepbound. Those are the FDA-approved products, each for the uses on its own label. A compounded semaglutide or tirzepatide isn't one of them and doesn't share their approval. FDA's page on unapproved GLP-1 drugs says so directly: "compounded drugs are not FDA approved," and "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."

The semaglutide and tirzepatide pages list each approved product with its source and the date it was checked.

FDA's lists for 503A compounding

Bulk drug substances (active ingredients) can be nominated for FDA's 503A bulk drug substances list. Under an interim policy, while it evaluates the nominations, FDA sorts the nominated substances into three categories. Its list of them, updated May 14, 2026, names the categories:

  • Category 1: "Bulk Drug Substances Under Evaluation"
  • Category 2: "Bulk Drug Substances that Raise Significant Safety Risks"
  • Category 3: "Bulk Drug Substances Nominated Without Adequate Support"

A category is a compounding status, not an FDA approval: a compounded drug isn't FDA-approved, whatever category its ingredient is in. Substances move between categories when nominations change, so check the date on FDA's list. FDA has also said it doesn't intend to place substances nominated on or after January 7, 2025, into these categories (checked November 1, 2026; the list was still dated May 14, 2026).

Schedule III

The federal Controlled Substances Act places controlled substances in five schedules, I to V. DEA describes each schedule by whether its substances have an accepted medical use in the US and by their potential for abuse and dependence. Schedule III substances have an accepted medical use and less potential for abuse than those in Schedules I and II.

DEA lists anabolic steroids, including testosterone, in Schedule III, and federal regulations name testosterone in Schedule III's list of anabolic steroids (21 CFR 1308.13(f)).

What that means for a prescription, in plain terms, from DEA's manual for pharmacists:

  • The prescription has to be valid. DEA says a prescription for a controlled substance must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.
  • Refills are limited. A Schedule III prescription can be refilled only if the prescription authorizes it, and no more than five times within six months of the date it was issued. After five refills or six months, whichever comes first, a new prescription is needed (21 CFR 1306.22(a)).
  • State law applies too. Federal and state controlled-substance laws are designed to work together, so your state's rules also apply.

This is a summary of DEA's published guidance, not legal advice. Your pharmacist can tell you how it applies to your prescription. Transfers, state rules and the records worth keeping are covered in why testosterone is a Schedule III controlled substance.

In the Peptimes Library, testosterone entries show "DEA Schedule: Schedule III" with "Controlled substance · prescription only". No other Library entry shows a DEA schedule.

Dietary supplement

Dietary supplements are regulated differently from drugs. In FDA's words, "by law, FDA does not approve dietary supplements or their labeling." Under the Dietary Supplement Health and Education Act, FDA doesn't have the authority to approve supplements before they're marketed, and the companies that make and sell them are responsible for making sure their products meet the law's requirements. A product sold as a dietary supplement isn't an FDA-approved drug.

The status labels in the Peptimes Library

Each Library entry has its own page, with one status label at the top. The label records what the Library's sources showed for that compound. It's a starting point, and it can be out of date. Here's what each label means:

Peptimes Library status labels and what each one means
LabelMeaning
FDA ApprovedAn FDA-approved product exists for at least one use. The page says which.
Not FDA-ApprovedNo FDA-approved product.
Approved outside the USApproved by a regulator in another country, not by the FDA.
Phase 1 / 2 / 3 TrialsInvestigational: in clinical trials, not FDA-approved.
Dietary SupplementSold as a supplement, not an FDA-approved drug.
CompoundableNot FDA-approved as a product; FDA rules allow pharmacies to compound it.
Compounding RestrictedFDA lists it as raising significant safety risks for compounding (its "Category 2").

The trial labels name their phase: "Phase 1 Trials", "Phase 2 Trials" or "Phase 3 Trials". Further down, each Library page has an "FDA & Legal Status" section. It repeats the status (for a Compounding Restricted entry, as FDA's Category 2), and has a "Compounding" row and, for testosterone, the DEA schedule. How the Library works covers searching it and the "Your doses" card.

A Peptimes Library page for GHK-Cu showing its status label, Not FDA-Approved, below the compound's name.

Status can change

FDA approves new products and new uses, approved products are discontinued, and FDA updates its compounding categories (the list of 503A categories cited here was updated May 14, 2026). DEA's list of controlled substances is revised over time, too. A status is only as current as the date it was checked.

Each compound page on this site gives the status with its source and the date it was checked. Before relying on a status, check the current source yourself: Drugs@FDA for approvals, FDA's compounding pages for compounding categories, and DEA's schedules for controlled substances.

The compound pages on this site, by label

Each compound page shows the label the Peptimes Library gives it, and the US status behind it with sources and the date each was checked. A label describes the Library entry, not the specific product you have.

Compound pages on this site, grouped by their Library status label
LabelCompound pages
FDA ApprovedAbaloparatide, Acarbose, Anastrozole, Baricitinib, Cabergoline, Calcitonin (salmon), Cetrorelix, Clomiphene, Desmopressin, Deuruxolitinib, Dulaglutide, Dutasteride, Estradiol, Exemestane, Exenatide, Finasteride, Follitropin, Galantamine, Ganirelix, HCG, HGH (Somatropin), HMG, Icatibant, L-Carnitine, Lanreotide, Letrozole, Leuprolide, Linaclotide, Liraglutide, Lixisenatide, Lonapegsomatropin, Mecasermin, Melanotan I, Metformin, Methylene blue, Minoxidil, Nafarelin, Octreotide, Orforglipron, Oxytocin, Pasireotide, Pegvisomant, Plecanatide, Progesterone, PT-141, Rapamycin, Ritlecitinib, Semaglutide, Setmelanotide, Somapacitan, Somatrogon, Spironolactone, SS-31, Tadalafil, Tamoxifen, Teduglutide, Teriparatide, Tesamorelin, Testosterone, Testosterone cypionate, Tirzepatide, Tretinoin, Triptorelin, Upadacitinib
Approved outside the US5-HTP, Anamorelin, Bromantane, Buserelin, Cerebrolysin, Coenzyme Q10, Cortexin, DSIP, Ecnoglutide, Efpeglenatide, Glutathione, Mazdutide, Noopept, Selank, Semax, Thymagen, Thymalin, Thymosin Alpha-1
CompoundableGonadorelin, Naltrexone, Sermorelin
Compounding RestrictedGHRP-2, GHRP-6, Ipamorelin, Kisspeptin-10, MK-677
Phase 3 TrialsAleniglipron, Cagrilintide, CagriSema, Eloralintide, Enicepatide, Maridebart cafraglutide, Pemvidutide, Petrelintide, Retatrutide, Survodutide, VK2735, Zenagamtide
Phase 2 TrialsAngiotensin 1-7, ARA-290, Bioglutide, Efinopegdutide, NSI-189, Thymosin Beta-4
Phase 1 TrialsPegapamodutide
Not FDA-Approved5-Amino-1MQ, Adamax, AHK-Cu, AICAR, AOD-9604, Apelin, Argireline, B7-33, BPC-157, Bronchogen, Cardiogen, Carnosine, Cartalax, Chonluten, CJC-1295, CJC-1295 no DAC, Cortagen, Cyclic Glycine-Proline, Dihexa, Enclomiphene, Epithalon, Estriol, Follistatin 344, Fox04-DRI, Fragment 176-191, GHK-Cu, Ghrelin, GIP, Hexarelin, Humanin, Humanin G, IGF-1 DES, IGF-1 LR3, Klotho, KPV, Larazotide, Livagen, LL-37, Matrixyl, Melanotan II, MGF, MOTS-c, N-Acetyl Epithalon Amidate, N-Acetyl Selank, N-Acetyl Semax Amidate, NAD+, Orexin-A, Ovagen, Oxyntomodulin, P21, Pancragen, PE-22-28, PEG-MGF, Pinealon, Prostamax, Serelaxin, SLU-PP-332, Snap-8, Somatorelin, Syn-Ake, TB-500, TB4-Sulfoxide, Tesofensine, Testagen, Thymulin, Vesugen, Vilon, VIP
Dietary Supplement7-Keto-DHEA, Collagen Peptides, Creatine, Crystagen, DHEA, Melatonin, Nicotinamide Riboside, NMN, Pregnenolone, Ubiquinol

Keeping your own record

Peptimes is a tracking app for the medicines and compounds you already use. You log each dose you take, get reminders at the times you set, and can export your records as CSV or JSON to bring to an appointment (how to export your records). Its Library shows the status labels above as a starting point. We don't sell peptides.

See how Peptimes works as a GLP-1 tracker and as a TRT tracker.

Questions people ask

Is compounded semaglutide FDA-approved?

No. FDA says compounded drugs are not FDA approved, and it doesn't review them for safety, effectiveness or quality before they're marketed. Approval belongs to specific products such as Ozempic, Wegovy and Rybelsus, and a compounded product doesn't share it, even with the same active ingredient. The semaglutide page lists the approved products and their sources.

Is compounded tirzepatide FDA-approved?

No, for the same reason: compounded drugs are not FDA approved. Mounjaro and Zepbound are the approved tirzepatide products. The tirzepatide page lists them with their sources.

What is the difference between FDA approved and FDA cleared?

"Approved" is the word for drugs, and for the highest-risk medical devices. Many other medical devices are "cleared": FDA agrees they're substantially equivalent to a device already legally on the market. A drug is never "cleared". And a company or product being registered or listed with FDA doesn't mean it's approved.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

Both compound drugs. A 503A pharmacy compounds under section 503A of the Federal Food, Drug, and Cosmetic Act, isn't held to FDA's manufacturing (CGMP) requirements. A 503B outsourcing facility registers with FDA, which is its main overseer, inspects it on a risk-based schedule and holds it to CGMP. Drugs from either one are not FDA-approved.

What does Category 2 mean for a peptide?

It's one of FDA's three categories for substances nominated for 503A compounding: substances FDA has found raise significant safety risks in compounding. A category is a compounding status, never an approval, and leaving Category 2 doesn't make anything FDA-approved. The Peptimes Library shows these entries as "Compounding Restricted".

How do I check if a medicine is FDA approved?

Search Drugs@FDA (fda.gov/drugsatfda) for the brand name or active ingredient, and check that the product, its dosage form and route match yours, and its marketing status. A listing on DailyMed isn't proof of approval. Reading an FDA drug label walks through it.

Sources

Coming soon to the App Store

Coming soon to Google Play

See planned pricing